Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Simvastatin and pregnancy]

C Freyssinges1, M B Ducrocq

  • 1Laboratoires MSD-Chibret, Paris.

Therapie
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Simvastatin exposure during pregnancy did not significantly alter pregnancy outcomes in prospective cases, with results comparable to the general population, excluding induced abortions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy.

Reproductive toxicology (Elmsford, N.Y.)·1996
Same author

Effects of transdermal clonidine in young and elderly patients with mild hypertension: evaluation by three noninvasive methods of blood pressure measurement.

Journal of cardiovascular pharmacology·1987
Same author

[A secondary effect of converting enzyme inhibitors: cough].

Presse medicale (Paris, France : 1983)·1987
Same author

[Treatment of arterial hypertension. Comparative effectiveness of the day care hospital and classical hospitalization].

Presse medicale (Paris, France : 1983)·1983
Same author

[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)].

La Nouvelle presse medicale·1981
Same author

[Interest in multifactorial prevention of coronary disease in hypertensives: use of beta blockaders].

Acquisitions medicales recentes·1979
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Area of Science:

  • Pharmacovigilance
  • Reproductive Toxicology
  • Clinical Obstetrics

Context:

  • Assessing the safety of simvastatin (Zocor, Lodales) during pregnancy is crucial due to its widespread use.
  • Pregnancy registries are vital for monitoring drug exposure and outcomes.
  • Information was sought from pharmaceutical firms regarding simvastatin exposure in pregnant women.

Purpose:

  • To evaluate the pregnancy outcomes following maternal exposure to simvastatin.
  • To compare pregnancy and neonatal outcomes in women exposed to simvastatin with general population data.
  • To prospectively analyze the safety profile of simvastatin during gestation.

Summary:

  • This study analyzed 169 women exposed to simvastatin during pregnancy.
  • Of 125 documented pregnancies, outcomes included live births (66 normal), induced abortions (40), spontaneous abortions (12), premature births (4), malformations (3), and fetal deaths (2).

Related Experiment Videos

  • Prospective analysis, excluding induced abortions, indicated pregnancy outcomes were comparable to the general population.

    • Impact:

    • Provides crucial data on the safety of simvastatin use in pregnant women.
    • Informs clinical decision-making for healthcare providers managing pregnant patients requiring statin therapy.
    • Contributes to the ongoing pharmacovigilance of lipid-lowering agents during pregnancy.